HLA-B*57:01 typing in a Malaysian cohort: implications of abacavir hypersensitivity in people living with HIV

Pharmacogenomics. 2023 Sep;24(14):761-769. doi: 10.2217/pgs-2023-0136. Epub 2023 Sep 28.

Abstract

Background: Abacavir (ABC) in combination with other antiretroviral drugs, is used to treat people living with HIV (PLWH). However, it is linked to a fatal hypersensitivity reaction in susceptible individuals, and is strongly associated with the HLA-B*57:01 allele. Materials & methods: A total of 152 patients, 50 PLWH and 102 HIV-1 negative patients, were assessed for the HLA-B*57:01 allele through a sequence-specific primer PCR. Results: All PLWH tested negative for the HLA-B*57:01 allele, but two HIV-negative patients were found to have HLA-B*57, with one of them expressing the HLA-B*57:01 allele. Conclusion: Given the low prevalence of this risk allele in the population, testing for the presence of HLA-B*57:01 in PLWH may not provide significant benefit for the reported population.

Keywords: HIV; HLA-B*57:01; Malaysia; abacavir; hypersensitivity reaction.